Details of the Drug

General Information of Drug (ID: DM8J3VY)

Drug Name
Beremagene geperpavec
Indication
Disease Entry ICD 11 Status REF
Epidermolysis bullosa EC3Z Phase 3 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D8CW9E

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Collagen VII (COL7A1) TTBCOKN CO7A1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04491604) A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). U.S.National Institutes of Health.
2 Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022 Dec 15;387(24):2211-2219.